Viewpoint on CANDOR: A Unique Combination for Patients with Multiple Myeloma at First Relapse

Host: Jennifer Caudle, DO <br> Guest: Joseph Mikhael, MD <br> <p>Many patients with multiple myeloma receive an immunomodulatory agent (IMiD) as part of their initial treatment, leading to a growing interest in what a patient’s next treatment should be if they don’t respond or become refractory to IMiDs. With the approval of an IMid-free regimen based on the CANDOR study results, these patients now have a treatment option.² Drs. Jennifer Caudle and Joseph Mikhael discuss the regimen and the CANDOR study, including the key findings that came out of the study.</p> <p>1. Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. <em>Lancet</em>. 2020;396:186-197.<br />2. KYPROLIS^® (carfilzomib) prescribing information, Onyx Pharmaceuticals Inc., an Amgen Inc. subsidiary.</p> <p style="text-align: right;">USA-171-81544 9/2021</p>